Glenmark Pharmaceuticals has announced the discovery of a new molecule for oncology treatment and would file an application for phase-I trials in the fourth quarter of FY12. Developed at Glenmark's Switzerland-based research centre, the GBR 401 molecule is an anti-CD19 monoclonal antibody primarily targeted for treating lymphoma and leukemia of B-cell origin. In addition, the molecule also has potential to treat disorders like rheumatoid arthritis. The molecule is in the same segment of anti-cancer biotech product rituximab, which had annual global sales of $6 billion.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: